Aethlon Medical Inc. (AEMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 6, 2026, details a material definitive agreement entered into by Aethlon Medical, Inc. (Nevada corporation). The report covers a registered public offering that closed on July 7, 2026, following the effectiveness of the registration statement on July 6, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4,000,000.
- Net Proceeds: Approximately $3,335,000 after deducting placement agent fees, expenses, and estimated offering costs.
- Offering Price: $0.71 per share (combined price for one share of Common Stock or Pre-Funded Warrant and one Common Warrant).
- Securities Issued:
- 263,000 shares of Common Stock.
- 5,633,009 Common Warrants (exercise price $0.71).
- 5,370,009 Pre-Funded Warrants.
- 225,320 Placement Agent Warrants (4.0% of shares placed, exercise price $0.71, exercisable after 6 months).
- Placement Agent Fees: 6.25% of gross proceeds ($260,000) plus $100,000 for expense reimbursement.
- Use of Proceeds: Working capital for general corporate purposes.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain investors and a Placement Agency Agreement with Maxim Group LLC. Key contractual restrictions include:
- Lock-Up Period: Officers and directors agreed not to sell or transfer Company securities for 90 days following the closing.
- Issuance Restrictions: The Company agreed not to issue or announce the issuance of securities for 90 days post-closing.
- Variable Rate Transaction Restriction: The Company cannot effect variable rate transactions for one year without prior written consent from Maxim Group LLC.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to fund working capital and general corporate operations. The filing notes that the Common Warrants are exercisable upon issuance if specific "Pricing Conditions" under Nasdaq rules are met; otherwise, they become exercisable upon stockholder approval. The filing does not provide specific forward-looking guidance on revenue or profitability, nor does it detail specific risks beyond standard contractual obligations and market conditions inherent in the offering structure.
Investor Verification Checklist
- Verify the final number of shares issued and the exact net proceeds received after all closing adjustments.
- Confirm whether the "Pricing Conditions" were met to determine the immediate exercisability of the Common Warrants.
- Review the attached Exhibits 4.1, 4.2, and 4.3 for full terms of the warrants, including anti-dilution provisions or cashless exercise rights.
- Monitor the Company's cash burn rate to assess the runway provided by the $3.335 million in net proceeds.
- Check for any subsequent filings regarding stockholder approval if the warrants were not immediately exercisable.